Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine with or without bevacizumab as adjuvant treatment for colorectal cancer
ISRCTN45133151Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Capecitabine with Capecitabine + bevacizumab (2 arms). Primary endpoint: Disease-free survival at 3 years. Started Jul 2005; status: completed.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN45133151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN45133151.